Covaxin maker Bharat Biotech's nasal vaccine ready to take on new covid strains
New Delhi: Bharat Biotech International Ltd, which developed the covaxin vaccine to protect against earlier variants of covid-19, says its intranasal and injectable vaccine platforms are ready to be adapted for new strains of the disease.
India has recorded 5,755 active covid cases, according to the Union health ministry's data issued on Sunday. The nation also reported four new fatalities in the last 24 hours, taking the total covid death toll since 1 January to 59.
Health officials have identified two new JN.1 covid variants as the cause of the fresh wave of the infectious disease.
Suchrita Ella, managing director of Bharat Biotech, said the company's nasal vaccine iNCOVACC is 'specifically designed for flexibility to adapt to circulating strains, protection in upper respiratory tract, and easy administration without injections".
'Bharat Biotech's covid-19 vaccine platforms, both the injectable and intranasal versions, are enabled for adaptation. However, any decision to restart production is contingent upon regulatory agency approvals," she said in an email interview.
'We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," Ella said, adding that the company is monitoring the situation and is "well positioned to respond effectively".
Also read | Covid cases are rising again. Should we be worried?
Bharat Biotech and Serum Institute of India manufactured billions of doses of vaccines for Indians and for supplying to more than 100 countries during the first few waves of the covid pandemic. The last covid vaccine batches were manufactured a year ago, with no visibility on new stocks.
Dr. Soumya Swaminathan, a former chief scientist at the World Health Organization (WHO), recently emphasized the need for vaccine manufacturers to update their formulas based on new variants, warning that vaccines developed for the original covid strain would offer little protection now.
Bharat Biotech halted production of covaxin due to a decline in demand in early 2022 and destroyed significant quantities of its vaccine stock. 'Subsequently, we proceeded with the destruction of about 200 million doses of bulk and about 50 million doses of vaccines in vials," Ella said.
Asked if booster doses should be given to high-risk populations, Ella said that remained subject to national regulatory approval.
Also read | India steps up surveillance as covid-19 cases surge in Hong Kong and Singapore
India's covid preparedness
The Union health ministry, while stating that most current covid cases are mild, has directed states and union territories to increase testing and ensure medical preparedness across health facilities, reviewing the availability of oxygen, isolation beds, ventilators, and essential medicines.
A nationwide mock drill was conducted last week to assess the functionality of oxygen supply systems in hospitals.
The Union government has also advised the public to practise covid-appropriate behaviour, especially avoiding crowded places when unwell and seeking medical intervention.
State and district surveillance units are also closely monitoring cases of influenza-like illness (ILL) and severe acute respiratory illness (SARI). As per government guidelines, all admitted SARI patients and 5% of ILI cases are to be tested for covid.
Scientists at the Indian Council of Medical Research (ICMR) are conducting genome sequencing of positive samples to track the variants.
The latest covid wave is attributed to two new coronavirus variants—NB.1.8.1 and LF.7, which are mutations of the Omicron offspring JN.1 variant. Kerala has reported the maximum number of covid cases this year, at 1,373, followed by Maharashtra (510), Delhi (457), Gujarat (461), and West Bengal (431).
According to the Union health ministry, 760 people have recovered from covid in the last 24 hours, bringing the total number of recoveries this year to 5,484.
Also read | The official 'data fog' on India's covid toll has finally cleared up. Here's what we know now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
Safdarjung hospital starts DM in nephrology training from 2025 session
New Delhi: Vardhman Mahavir Medical College (VNMC) and Safdarjung Hospital have become Delhi's third institutions to start the Doctorate of Medicine (DM) in the nephrology training programme from the 2025 session. Previously, only AIIMS and RML Hospital offered this course. Dr Sandeep Bansal, the medical superintendent at Safdarjung Hospital, confirmed the allocation of three annual seats for DM in nephrology. "All three positions are being secured by candidates ranking within the top 10," he said. Principal of VNMC, Dr Geetika Khanna, expressed pride in launching this course. She emphasised the necessity of an additional workforce through postgraduate programmes, citing substantial patient numbers. Dr Himanshu Verma, who heads the nephrology department at Safdarjung Hospital, stated that approximately 6,000-7,000 kidney patients seek treatment at the hospital each month. India faces a significant shortage of nephrologists and dialysis specialists due to the increasing number of kidney-related health issues. Statistics indicate that 10% of Indians suffer from kidney-related conditions. The country has an expanding population of chronic kidney disease patients, with roughly 175,000 new end-stage renal disease cases annually. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Mundfalten reduzieren: Besser als 'Höhle der Löwen' Produkte Apotheken Gesundheit Mehr erfahren Undo The nation incurs significant expenses for dialysis and transplant treatments. The govt's Pradhan Mantri National Dialysis Programme assists financially challenged patients. Despite having excellent nephrologists and transplant surgeons, India requires more specialists to handle the increasing population of kidney patients, particularly considering the country's size. Qualified nephrologists are essential to reduce healthcare costs through early identification and prevention of kidney ailments.
India.com
17 hours ago
- India.com
Acute Myeloid Leukemia: Expert Explains Why This Aggressive Blood Cancer Is Rising Fast In India
AML Awareness Month is marked each June. In India, where infectious diseases dominate public health narratives, a quieter and deadlier crisis is unfolding- Acute Myeloid Leukemia (AML). About 10-15% of all leukaemia cases, AML is a rapidly progressing blood cancer that requires immediate intensive treatment. Yet, delayed diagnosis and poor access to specialised care are making outcomes grim for hundreds of Indians each year. Who is at Risk? Dr Ashay Karpe, Consultant Haematologist and Bone Marrow Transplant Physician, SUNACT Cancer Institute, Mumbai, says, "AML is a cancer of blood and bone marrow that advances quickly, leading to an overproduction of immature white blood cells. While globally it is often diagnosed in the elderly, Indian patients tend to be younger, with many cases presenting in people in their 30s and 40s." According to data from the National Cancer Registry Programme (NCRP), the incidence of AML in India is estimated to be between 0.8 and 5 per 100,000 population. Where and Why Does Diagnosis Lag? In the early stages, AML is a master of disguise. Persistent tiredness, low-grade fever, or frequent bruising are often brushed off as minor or seasonal issues by patients and frontline doctors alike. This tendency, particularly in smaller towns and rural belts, allows the disease to progress unchecked. "AML doesn't give you much time," says Dr Ashay. "By the time a patient sees a specialist, they have often already lost critical ground. Early intervention is the difference between life and loss.' Unfortunately, the early intervention depends on access, and access is so far from equitable. From Chemo to Targeted Therapy Standard AML Therapy isn't just intensive- it's expensive. But the treatment landscape is evolving. Recent advancements in AML treatment like Venetoclax and targeted therapies such as Ivosidenib, are helping clinicians treat patients more effectively, especially those with specific genetic mutations. The arrival of Ivosidenib brings a ray of hope for those with the IDH1 mutation. These drugs are changing the paradigm of AML care, offering new hope where conventional therapy might fail or be too risky for elderly or frail patients. What can change the Odds? Dr Karpe, a leading haematologist, warns: 'In India, without expert guidance at diagnosis, we are already several steps behind global standards. Early bone marrow biopsy and cytogenetic profiling are not luxuries-they are lifesavers.' He underscores that proper counselling and early referral improve survival by allowing timely intensive chemotherapy and transplant planning. 'Patients arrive late, often battling infections for organ failure, says Dr Karpe. In AML, that delay is often irreversible.' Dr Karpe highlights the need to focus on basic upgrades: 1. Training general practitioners to spot danger signs early 2. Ensuring bone marrow testing facilities in public hospitals 3. Including newer targeted drugs and diagnostics as part of the national care He adds, 'A simple CBC (Complete Blood Count) can be the first clue, but someone has to ask for it at the right time. This is why it matters Now." AML might not affect millions, but every case is a race against the clock. In a nation with a rapidly shifting disease landscape, early diagnosis, fast-track specialist care, and policy-level intervention could stop this disease from becoming a death sentence. India has tools. What it needs now is urgency.
Time of India
a day ago
- Time of India
Deadline diet India's young workforce faces cardiac scare
Young Indians are increasingly facing heart issues. Doctors report a rise in cardiac cases among those in their 20s and 30s. Stress, lack of sleep, and unhealthy lifestyles are major factors. Sedentary jobs and poor diets contribute to the problem. Even post-Covid inflammation increases the risk. Sales of heart-related drugs have significantly increased. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads For 31-year-old techie Kumar, long hours at work carrying well into the night often led to stress eating, coupled with an occasional drink (or two) to "take off the edge".The excesses magnified over the weekend, till one day when what he suspected was an episode of indigestion turned out to be a heart attack. Kumar, who doesn't want to reveal his full name, has now been put on a strict diet by his doctor. He has been asked to cut out all unhealthy food, stop eating out and is not an isolated case. Leading cardiologists are sounding the alarm bells as they see an increase in people in their 20s and 30s being hospitalised for cardiac issues. Stress, lack of sleep, pollution and working at odd hours have all contributed to the increase in heart disease among young people, said noted cardiologist Naresh Trehan."The numbers are worrisome; out of 34 beds in my ICU, nine are occupied by patients under 40," said Naveen Bhamri, vice-chairman of cardiology at Max Super Speciality Hospital in New Delhi's Shalimar Bagh, who performed an angioplasty on a 39-year-old this week. "A majority of my patients are in their 20s and 30s, who see long periods of inactivity due to being stuck at their desks, stressed out by the constant urban hustle and pressure to hit corporate targets."Nishith Chandra, director, interventional cardiology at Fortis Escorts Heart Institute in the national capital, said he is seeing 10-20 patients in the age group of 20-30 years every month with heart-related key drivers behind this trend are sedentary lifestyle, lack of exercise, high stress, poor sleep and mental health issues, Chandra said. "Undiagnosed hypertension, post-Covid heart inflammation, use of steroids and unsafe gym supplements, smoking, alcohol and recreational drug use are some other factors," he across the country are reporting increased cases of young professionals having cardiovascular diseases, sudden cardiac arrests and heart attacks."Not all of them have the typical triggers like diabetes, hypertension, obesity and family history. Recent data shows that one in four individuals having heart attacks are aged 40 and under," said M Sudhakar Rao, consultant - cardiology at Manipal Hospital, Sarjapur, Bengaluru Tight deadlines and work pressure, constant hustle culture and impending burnout are causing Indian professionals to remain in sedentary positions for most of the day, get less sleep, and turn to unhealthy, processed foods - all of which can contribute significantly to the risk of heart attacks, say medical is the diabetes and hypertension capital of the world, and people are genetically more predisposed to getting heart diseases, often earlier than their counterparts in the West, said Mukesh Goel, senior consultant - cardiothoracic and heart and lung transplant surgery at Delhi's Indraprastha Apollo Hospitals. "There's a difference of 10-15 years with the West."Telehealth consultation data from Plum shows two-thirds of cardiac consultations come from the 25-40 age group, showing a premature cardiovascular ageing in India's prime working demographic."We've observed that 71% of Indian working professionals are at moderate risk of chronic disease, showing warning signs across blood pressure, diabetes, cholesterol and obesity," Saurabh Arora, cofounder of the insurtech startup, told has increased the risk further, said Trehan. "People who got serious Covid actually have much higher chance of developing heart disease because there is inflammation of the arteries, and the heart muscle became weak. So, if those who got serious Covid were not checked out then they should get it now".Sales of drugs in the cardiac category have risen almost 50% in five years to ₹30,723 crore in the 12 months through May 2025, according to data from market research firm PharmaTrac."Consumption of lipid-lowering agents, antianginal therapies and heart failure therapies have almost doubled in the last five years with Indians experiencing heart disease 5-10 years earlier than the global average. The age group has now come down to 30-40 years from earlier 50-60 years, said Sheetal Sapale, vice-president, commercial at of cardiac products increased 11.7% in 2024 compared with the year before.
